OWP Pharmaceuticals, Inc. (OWP) is a privately held, neuroscience specialty pharmaceutical company, dedicated to developing and commercializing novel oral liquid formulations and supporting global philanthropy.
OWP announced its partnership with EVERSANA™, the pioneer of next generation commercial services to the global life sciences industry, to launch and commercialize its portfolio of oral liquid formulations aimed to treat neuroscience disorders.
OWP will utilize a number of EVERSANA’s fully integrated commercialization services that include market access, agency services, clinical and commercial field teams, channel management, patient services, health economics and outcomes research, and compliance, with each service optimized by data and predictive analytics.
EVERSANA ended 2021 with the following announcements:
- Real-World Data Agreement with Janssen to augment development of chronic disease care therapies. The agreement will drive a deeper understanding and enhance the design of clinical trials through regulatory-grade, auditable determination of clinical endpoints, thus enabling studies that can reduce clinical trial timelines and offer important signals about how therapies perform in real world settings.
- EVERSANA completed its acquisition of Intouch Group®, a full-service global agency network serving the pharmaceutical industry. Under terms of the agreement announced in October 2021, Intouch’s industry-leading creative and media services, enterprise solutions and data analytics will join EVERSANA’s fully integrated commercialization services platform.
Takeaway: OWP Pharmaceutical leveraging EVERSANA’s leading position of providing integrated commercialization solutions